inotuzumab ozogamicin,blinatumomab
pfizer,amgen,ucb pharmaceuticals
['leusm', 'blinatumomab', 'inotuzumab', 'inotuzumab ozogamicin']
congress #eha2023 | describes a phase ii trial of hyper-cvad + inotuzumab ozogamicin &amp; blinatumomab in pts with nd ph-ve b-all. n=72. 100% of 56 patients achieved cr at any time. 95% of 62 evaluable patients reached mrd negativity #leusm #allsm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm